

4. Autti-Ramo I, Makela M, Sintonen H, Koskinen H, Laajalahti L, Halila R, et al. Expanding screening for rare metabolic disease in the newborn: an analysis of costs, effect and ethical consequences for decision-making in Finland. *Acta Paediatr* 2005;94(8):1126-36.
5. Cavedon CT, Bourdoux P, Mertens K, Van Thi HV, Herremans N, de Laet C, et al. Age-related variations in acylcarnitine and free carnitine concentrations measured by tandem mass spectrometry. *Clin Chem* 2005;51(4):745-52.
6. Newborn screening: toward a uniform screening panel and system--executive summary. *Pediatrics* 2006;117(5 Pt 2):S296-307.
7. Feuchtbaum L, Lorey F, Faulkner L, Sherwin J, Currier R, Bhandal A, et al. California's experience implementing a pilot newborn supplemental screening program using tandem mass spectrometry. *Pediatrics* 2006;117(5 Pt 2):S261-9.
8. Kaye CI, Accurso F, La Franchi S, Lane PA, Northrup H, Pang S, et al. Introduction to the newborn screening fact sheets. *Pediatrics* 2006;118(3):1304-12.
9. Osorio JH, Pourfarzam M. [Determination of normal acylcarnitine levels in a healthy pediatric population as a diagnostic tool in inherited errors of mitochondrial fatty acid beta-oxidation]. *An Pediatr (Barc)* 2007;67(6):548-52.
10. Kaye CI, Livingston J, Canfield MA, Mann MY, Lloyd-Puryear MA, Therrell BL, Jr. Assuring clinical genetic services for newborns identified through U.S. newborn screening programs. *Genet Med* 2007;9(8):518-27.
11. Joshi SN, Venugopalan P. Clinical characteristics of neonates with inborn errors of metabolism detected by Tandem MS analysis in Oman. *Brain Dev* 2007; 29(9):543-6.
12. Wilcken B. The consequences of extended newborn screening programmes: Do we know who needs treatment? *J Inherit Metab Dis* 2008 Feb 22. (Epub ahead of print).
13. Copeland S. A review of newborn screening in the era of tandem mass spectrometry: what's new for the pediatric neurologist? *Semin Pediatr Neurol* 2008;15(3):110-6.
14. Fingerhut R, Olgemoller B. Newborn screening for inborn errors of metabolism and endocrinopathies: an update. *Anal Bioanal Chem* 2009;393(5):1481-97.

iniciar un tratamiento antibiótico precoz y eficaz según estudios de sensibilidad a los antimicrobianos.

Aportación del cribado:

Prevención de la deshidratación y la desnutrición en los recién nacidos con FQ. También existen beneficios en la función pulmonar al retrasar la aparición de infecciones mediante diferentes abordajes terapéuticos que puede evitar el trasplante. Identificación del caso índice con sus posibles mutaciones por lo que se facilita a la familia una herramienta para la posible planificación familiar.

Artículos publicados y/o evidencias propias que documenten lo anterior.

1. Rommens JM, Zengerling S, Burns J, Melmer G, Kerem BS, Plavsic N et al. Identification and regional localization of DNA markers on chromosome 7 for the cloning of the cystic fibrosis gene. *Am J Hum Genet.* 1988; 43(5):645-63.
2. Gibson LE, Cooke RE. A test for the Concentration of Electrolytes in Cystic Fibrosis of the Pancreas Utilizing Pilocarpine by Iontophoresis. *Pediatrics* 1998; 102(1):230-1.
3. Cheillan D, Vercherat M, Chevalier-Porst F, Charcosset M, Rolland MO, Dorche C. False-positive results in neonatal screening for cystic fibrosis based on a three-stage protocol (IRT/DNA/IRT): Should we adjust IRT cut-off to ethnic origin?. *J Inherit Metab Dis.* 2005; 28(6):813-8.
4. Mérelle ME, Nagelkerke AF, Lees CM, Dezateux C. Cribaje (screening) de la enfermedad fibroquística en el recién nacido (Revisión Cochrane traducida). En: *La Biblioteca Cochrane Plus*, 2006 Número 2. Oxford: Update Software Ltd. Disponible en: <http://www.update-software.com>. (Traducida de *The Cochrane Library*, 2006 Issue 2. Chichester, UK: John Wiley & Sons, Ltd.).
5. Massie J, Curnow L, Tzanakos N, Francis I, Robertson CF. Markedly elevated immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testing. *Arch Dis Child* 2006; 91(3):222-5.
6. McKay KO. Cystic fibrosis: Benefits and clinical outcome. *J Inherit Metab Dis.* 2007; 30(4): 544-55.
7. Giusti R, Badwell A, Iglesias A. New York State cystic fibrosis consortium: the first 2.5 years of experience with cystic fibrosis newborn screening in an ethnically diverse population. *Pediatrics* 2007; 119(2):460-7.
8. Wilcken B. Newborn screening for cystic fibrosis: Techniques and strategies. *J Inherit Metab Dis* 2007; 30(4):537-43.
9. Ratjen F. Recent advances in cystic fibrosis. *Pediatr Respir Rev* 2008; 9(2): 144-8.

